Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its stake in Regeneron Pharmaceuticals by 30.1%, acquiring a total of 245,197 shares valued at approximately $155.6 million.
• Several other major institutional investors, including Vanguard Group and Goldman Sachs, also elevated their holdings in Regeneron during recent quarters, highlighting strong institutional interest in the stock.
• Regeneron reported $12.89 EPS for the most recent quarter, exceeding estimates, alongside a quarterly dividend of $0.88 scheduled for September 3rd, reflecting its strong financial performance.

Aberdeen Group plc raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 30.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 245,197 shares of the biopharmaceutical company's stock after acquiring an additional 56,746 shares during the quarter. Aberdeen Group plc owned approximately 0.22% of Regeneron Pharmaceuticals worth $155,647,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in REGN. Brighton Jones LLC boosted its position in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after purchasing an additional 686 shares in the last quarter. American Assets Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $427,000. CreativeOne Wealth LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $318,000. Gamco Investors INC. ET AL grew its position in shares of Regeneron Pharmaceuticals by 54.2% during the 4th quarter. Gamco Investors INC. ET AL now owns 563 shares of the biopharmaceutical company's stock valued at $401,000 after acquiring an additional 198 shares during the period. Finally, Evergreen Capital Management LLC grew its position in shares of Regeneron Pharmaceuticals by 362.9% during the 4th quarter. Evergreen Capital Management LLC now owns 3,865 shares of the biopharmaceutical company's stock valued at $2,753,000 after acquiring an additional 3,030 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $2.13 during trading hours on Tuesday, hitting $571.78. 852,619 shares of the stock were exchanged, compared to its average volume of 1,107,271. The company has a market cap of $60.60 billion, a price-to-earnings ratio of 14.41, a price-to-earnings-growth ratio of 1.93 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The stock has a 50-day moving average of $545.33 and a 200 day moving average of $593.59. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company posted $11.56 earnings per share. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analysts Set New Price Targets

REGN has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a "buy" rating and a $890.00 target price on the stock. Finally, Citigroup reaffirmed a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $829.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.